OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press510.17650/1818-8346-2014-9-1-6-10HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯTherapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapyЭффективность терапии пациентов с множественной миеломой, получавших в качестве первой линии трансплантацию аутологичных гемопоэтических стволовых клетокDarskayaYe. I.ДарскаяЕ. И.
Russian Federation
edarskaya@mail.ruMarami-ZonuziN. E.Марами-ЗонузиН. Э.
Russian Federation
OsipovYu. S.ОсиповЮ. С.
Russian Federation
EstrinaM. A.ЭстринаМ. А.
Russian Federation
BabenkoYe. V.БабенкоЕ. В.
Russian Federation
VavilovV. N.ВавиловВ. Н.
Russian Federation
AfanasievB. V.АфанасьевБ. В.
Russian Federation
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaНаучно-исследовательский институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России21072014916102107201421072014https://oncohematology.abvpress.ru/ongm/article/view/5

Therapy results of 91 patients with newly diagnosed multiple myeloma who received autologous hematopoietic stem cells transplantation are presented. According to our data, survival depends on the preransplant response and the amount of transplantations. 5-years progressionfree survival in patients, achieved pre-transplant complete or almost complete remission and received one auto-HSCT was 40 % compared with 18 % in patients who achieved only a partial response (p = 0.07). 10-years overall survival in patients received tandem auto-HSCT was40 % compared with 20 % in patients after one auto-HSCT. Statistically significant differences in 5-years progression-free survival (34 % after tandem auto-HSCT vs. 22 % after one auto-HSCT; p = 0.004) also were revealed.

В статье изложены результаты лечения 91 пациента с впервые выявленной множественной миеломой, получивших аутотрансплантацию гемопоэтических стволовых клеток (АТГСК). По нашим данным, выживаемость больных зависит как от ответа, полученного перед трансплантацией, так и от количества трансплантаций. Беспрогрессивная выживаемость (БПВ) в течение 5 лет больных, достигших перед трансплантацией полной или почти полной ремиссии и получивших одну АТГСК, составила 40 % по сравнению с 18 % у пациентов, достигших только частичного ответа (р = 0,07). Общая выживаемость больных в течение 10 лет после тандемной АТГСК составила 40 % по сравнению с 20 % в группе пациентов после одной АТГСК. Также статистически значимо различалась и БПВ в течение 5 лет: 34 % – после тандемной АТГСК по сравнению с 22 % после одной АТГСК (р = 0,004).

multiple myelomaautologous hematopoietic stem cells transplantationмножественная миеломатрансплантация аутологичных гемопоэтических стволовых клеток1. Rajkumar S.V., Blood E., Vesole D.H. et al. Phase III clinical trial of thalidomide plus dexamethasone ompared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative OncologyGroup. J Clin Oncol 2006;24:431–6.Rajkumar S.V., Blood E., Vesole D.H. et al. Phase III clinical trial of thalidomide plus dexamethasone ompared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative OncologyGroup. J Clin Oncol 2006;24:431–6.2. Rajkumar S.V., Hayman S., Gertz M.A. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.Rajkumar S.V., Hayman S., Gertz M.A. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.3. Rajkumar S.V., Hayman S.R., Lacy M.Q. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–3.Rajkumar S.V., Hayman S.R., Lacy M.Q. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–3.4. Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.5. Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008–14.Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008–14.6. Weber D.M., Chen C., Niesvizky R. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.Weber D.M., Chen C., Niesvizky R. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.7. Dimopoulos M., Spencer A., Attal M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.Dimopoulos M., Spencer A., Attal M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.8. Rajkumar S.V., Jacobus S., Callander N.S. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.Rajkumar S.V., Jacobus S., Callander N.S. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.9. Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.10. Brenner H., Gondos A., Pulte D. Recent ajor improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–6.Brenner H., Gondos A., Pulte D. Recent ajor improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–6.11. Raab M.S., Podar K., Breitkreutz I. et al. Multiple myeloma. Lancet 2009;374(9686):324–39.Raab M.S., Podar K., Breitkreutz I. et al. Multiple myeloma. Lancet 2009;374(9686):324–39.12. Harousseau J., Attal M., Leleu X. et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498–505.Harousseau J., Attal M., Leleu X. et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498–505.13. Barlogie B., Jagannath S., Vesole D.H. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–93.Barlogie B., Jagannath S., Vesole D.H. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–93.14. Attal M ., Harousseau J.L., Facon T. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. InterGroupe Francophone du Myélome. N Engl J Med 2003;349:2495–502.Attal M ., Harousseau J.L., Facon T. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. InterGroupe Francophone du Myélome. N Engl J Med 2003;349:2495–502.15. Sonnevel d P., Schmidt-Wolf I.G., van der Holt B. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMGHD4 trial. J Clin Oncol 2012;30(24):2946–55.Sonnevel d P., Schmidt-Wolf I.G., van der Holt B. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMGHD4 trial. J Clin Oncol 2012;30(24):2946–55.16. Attal M., Lauwers-Cances V., Marit G. et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–91.Attal M., Lauwers-Cances V., Marit G. et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–91.